Keros Therapeutics Inc

NASDAQ:KROS   3:57:09 PM EDT
75.37
-0.63 (-0.83%)
Earnings Announcements

Keros Reports Third Quarter 2020 Financial Results

Published: 11/10/2020 22:48 GMT
(KROS) - Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results.
Keros Therapeutics - Expects Cash & Cash Equivalents on Hand at Sept.
30 Will Fund Operating Expenses, Capital Expenditure Requirements Into H2 2022.
Keros Therapeutics Inc Qtrly Loss per Share $0.60.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.58

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.51

More details on our Analysts Page.